![Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine | Journal of Medicinal Chemistry Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c01627/asset/images/large/jm2c01627_0003.jpeg)
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine | Journal of Medicinal Chemistry
![Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2 | ACS Medicinal Chemistry Letters Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2 | ACS Medicinal Chemistry Letters](https://pubs.acs.org/cms/10.1021/acsmedchemlett.0c00521/asset/images/medium/ml0c00521_0008.gif)
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2 | ACS Medicinal Chemistry Letters
![Professor Steve Kisely - Centre of Research Excellence on Achieving the Tobacco Endgame - University of Queensland Professor Steve Kisely - Centre of Research Excellence on Achieving the Tobacco Endgame - University of Queensland](https://tobacco-endgame.centre.uq.edu.au/sites/tobacco-endgame.centre.uq.edu.au/files/styles/uq_core_small_portrait/public/ckfinder/images/Steve%20Kisely.png?itok=P05y1YCe)